| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Entera Bio Ltd.$1.66
-0.04 (-2.65%)
D 21Pipeline Score Richly Valued Biotech · Clinical
Market Cap
61.04 M
EPS
-0.26
P/E Ratio
-
Value Trade
53.90 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
2.25 M
Operating CF
-3.09 M
Total Assets
13.13 M
Total Liabilities
2.44 M
Equity
10.69 M
D/E Ratio
12,345
-4.62 %
Week
0.81 %
1 Month
-10.14 %
3 Month
-51.94 %
6 Month
-59.34 %
5 Year
-83.01 %
All Time
Cash Data
Cash Position
4.14 M
Monthly Burn
1.03 M
Runway
2.1 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
73.61 K
52 Week Range
0.91 - 3.22
% held by Insiders
18.3 %
% held by Institutions
15.97 %
Enterprise Value
49.56 M
Total Shares
46.63 M
Short %
0.4 %
Float Shares
25.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Entera Bio Ltd.
408Total events
5Upcoming
66Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 5
Event history 403
Q3 2026
Jun 22, 2026
▲FDA Feedback ReceivedEB-613FDA Meeting
FDA positive feedback on Phase 3 registrational protocol for EB613
postmenopausal osteoporosissource ↗
Jun 16, 2026
▲Poster PresentationEB612Presentation
Preclinical data for EB612 presented at ENDO 2026
hypoparathyroidismsource ↗
Jun 16, 2026
▲Poster PresentationEB618Presentation
Preclinical data for EB618 presented at ENDO 2026
obesity and metabolic disorderssource ↗
Jun 15, 2026
◆Poster PresentationEB612Presentation
Pre-Clinical Results for EB612 poster at ENDO 2026
hypoparathyroidismsource ↗
Jun 14, 2026
◆Oral PresentationEB-613Presentation
Late Breaking Oral Presentation of EB613 single tablet data at ENDO 2026
osteoporosissource ↗
Jun 13, 2026
◆Poster PresentationEB618Presentation
PK-PD Study Results for EB618 poster at ENDO 2026
obesity and metabolic disorderssource ↗
May 2026
◆FDA Feedback ReceivedEB-613FDA Meeting
FDA feedback expected within 60 days of submission
postmenopausal osteoporosissource ↗
Apr 20, 2026
◆Oral PresentationEB-613Presentation
KOL webinar on osteoporosis treatment landscape and EB613 opportunity
osteoporosissource ↗
Apr 2, 2026
▼Equity OfferingCorporate
Pricing of $10.0 million direct investment by BVF Partners with potential for up to $24.5 million total proceeds
Apr 2026
◆FDA Feedback ReceivedEB-613FDA Meeting
FDA feedback on streamlined Phase 3 protocol expected
postmenopausal women with osteoporosissource ↗
Drug Pipeline Intelligence
D21
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 739 of 911)
Percentile RankEntera Bio Ltd. faces pipeline headwinds (21/100), with $295M risk-adjusted pipeline value, led by EBP05 in Osteoporosis (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBP05 Small molecule | Osteoporosis | Phase 2 | NCT04003467 | 7% | $271M | COMPLETED | 161 | - | - | May 11, 2021 | - | Jun 28, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EB613 | osteoporosis | Phase 2 | 2026-05-28 | In a Phase 2 study involving 161 participants, Entera's EB613 demonstrated significant efficacy by meeting primary and secondary endpoints related to bone turnover biomarkers and bone mineral density, supporting its advancement to a Phase 3 trial for osteoporosis. Read More | Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation Read More | |
EB613 | osteoporosis | Phase 2 | 2026-05-28 | In a Phase 2 study involving 161 participants, Entera's EB613 demonstrated significant efficacy by meeting primary and secondary endpoints related to bone turnover biomarkers and bone mineral density, supporting its advancement to a Phase 3 trial for osteoporosis. Read More | Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation Read More | |
EB613 | osteoporosis | Phase 2 | 2026-05-28 | In a Phase 2 study involving 161 participants, Entera's EB613 demonstrated significant efficacy by meeting primary and secondary endpoints related to bone turnover biomarkers and bone mineral density, supporting its advancement to a Phase 3 trial for osteoporosis. Read More | Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ENTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ENTX▲ +22.3%on this news
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Entera Bio has received positive feedback from the FDA regarding its Phase 3 study protocol for EB613, an oral anabolic tablet for treating osteoporosis in postmenopausal women. The trial will involve approximately 750 participants and aims to demonstrate significant increases in hip bone mineral density after 12 months. The NDA submission is anticipated based on these results, with topline data expected in late 2028.
Read more →ENTXEntera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Entera Bio Ltd. presented promising preclinical results for its oral peptides EB612 and EB618 at ENDO 2026. EB612, designed for hypoparathyroidism, was found to restore calcium levels effectively in multiple models, while EB618 showed robust pharmacokinetics and positive effects on blood glucose levels in non-human primates. Both therapies are being developed in collaboration with OPKO Health and are progressing towards IND submissions, with EB612 expected to file in late 2026.
Read more →ENTXEntera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Entera Bio Ltd. announced that its EB613 tablet, an oral PTH(1-34) anabolic treatment for osteoporosis, has been selected for a Late Breaking Oral Presentation at the ENDO 2026 Annual Meeting. The presentation will showcase new clinical data supporting EB613 as the final candidate for a planned Phase 3 study in postmenopausal women. Additionally, other abstracts from Entera's oral peptide pipeline have been accepted for presentation.
Read more →ENTX▼ -5.1%on this news
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. announced its financial results for Q1 2026, highlighting significant progress in its oral peptide programs, including submissions for EB613, EB612, and EB618 at ENDO2026. The company has submitted a streamlined Phase 3 protocol for EB613 focused on treating postmenopausal osteoporosis and expanded its partnership with OPKO for EB612, aimed at hypoparathyroidism. Despite a net loss of $3.5 million, Entera's increased cash reserves bolster its operational capabilities for upcoming clinical trials. The company remains committed to innovation in underserved therapeutic areas.
Read more →ENTXEntera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Entera Bio Ltd. is set to host a Key Opinion Leader webinar on April 20, 2026, focusing on osteoporosis treatment and its candidate EB613. The event will feature discussions with leading experts on women's bone health and the current treatment landscape. EB613 has shown positive results in clinical trials, positioning it as a potential first oral anabolic therapy for osteoporosis.
Read more →ENTX▲ +10.5%on this news
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Entera Bio Ltd. has announced a private placement led by BVF Partners, raising approximately $10 million, with the potential for total proceeds of $24.5 million. The funds will be used to initiate a Phase 3 study of EB613, an oral treatment for postmenopausal women with osteoporosis. The placement is set to close around April 2, 2026.
Read more →ENTX▼ -11.5%on this newsshared move
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio announced its financial results for 2025, highlighting significant progress in its pipeline, including the submission of a Phase 3 protocol for EB613, an oral anabolic peptide for osteoporosis. The company aims to make anabolic treatment more accessible. Despite a net loss of $11.4 million, Entera is optimistic about its innovative oral peptide therapies.
Read more →ENTXEntera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Entera Bio has submitted a streamlined Phase 3 protocol to the FDA for EB613, an oral treatment for postmenopausal osteoporosis. The study aims to evaluate the drug's efficacy in increasing total hip bone mineral density (BMD) over 12 months. The new single tablet formulation is expected to enhance patient compliance and accelerate the path to approval, with topline results anticipated in late 2028.
Read more →ENTXEntera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
Entera Bio Ltd. announced that CEO Miranda Toledano will participate in the Leerink Partners Global Healthcare Conference 2026. The event will take place on March 11, 2026, in Miami, Florida. A live webcast will be available for those unable to attend in person, with a replay accessible for 365 days. Entera is known for its innovative oral peptide therapies.
Read more →ENTX▲ +13.1%on this news
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
Entera Bio Ltd. announced that several board members, including the Chairman, purchased shares in the company, reflecting their confidence in its future. This follows a previous purchase by the CEO. Entera is focused on developing oral peptide therapies, with promising clinical trial results for its lead candidate, EB613, aimed at treating osteoporosis.
Read more →ENTX▲ +27.9%on this news· ran to +46% by day 3shared move
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Entera Bio Ltd. has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. This leadership change comes as the company prepares to advance two oral peptide programs into clinical trials, including a Phase 3 study for EB613 in osteoporosis. Germano's extensive experience in the biopharmaceutical industry is expected to benefit Entera as it moves forward with its innovative therapies.
Read more →ENTXOPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
OPKO Health and Entera Bio have expanded their partnership to develop a first-in-class oral long-acting PTH tablet for hypoparathyroidism. The companies aim to file an IND application with the FDA by late 2026, leveraging Entera's N-Tab technology and OPKO's protein chemistry expertise. This collaboration seeks to provide a more convenient treatment option for patients currently reliant on daily injections.
Read more →ENTXEntera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Entera Bio has outlined its corporate priorities for Q1 2026, including the submission of its EB613 Phase 3 protocol to the FDA. The company is also progressing with its Next-Gen EB613 Phase 1 bridging study, with results expected soon. Additionally, Entera plans to accelerate its hypoparathyroidism program and is engaging in strategic partnership discussions.
Read more →ENTXEntera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
Entera Bio has expressed its congratulations to the FNIH-ASBMR-SABRE team following the FDA's qualification of total hip bone mineral density (BMD) as a regulatory endpoint for osteoporosis drug development. This qualification supports Entera's strategy for its oral treatment, EB613, which aims to provide a new anabolic option for patients. The FDA's decision is expected to simplify the path for Entera's future regulatory submissions.
Read more →ENTX▲ +6.2%on this newsshared move
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Entera Bio has announced promising new data for its EB612 program, which focuses on a long-acting oral parathyroid hormone (PTH) tablet for hypoparathyroidism. The preclinical results indicate a significantly longer plasma half-life and sustained calcium levels compared to existing treatments. This advancement aims to simplify treatment for patients, moving from multiple daily doses to a single daily tablet.
Read more →ENTXEntera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference. The event is scheduled for December 3, 2024, and will be held in Coral Gables, Florida. A live webcast of the discussion will be available for those who cannot attend in person, with a replay accessible for 90 days afterward. This engagement highlights Entera's efforts to connect with stakeholders and share insights on its development and future strategies.
Read more →ENTXEntera Bio Announces Third Quarter 2025 Financial Results and Business Updates
Entera Bio Ltd. reported its third quarter 2025 financial results, highlighting progress in several clinical programs, particularly EB613, an oral treatment for osteoporosis. The FDA's agreement to use bone mineral density as the primary endpoint for a Phase 3 study is seen as a major milestone. Data presented at major conferences have shown promising efficacy of EB613 in younger post-menopausal women. However, Entera continues to face financial losses and must navigate several risks associated with clinical trials and regulatory approvals.
Read more →ENTX▼ -7%on this news
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
Entera Bio has presented positive clinical data from its Phase 2 trial of EB613 at the NAMS 2025 meeting. The oral PTH(1-34) treatment demonstrated significant increases in bone mineral density among early postmenopausal women. Entera plans to initiate a global Phase 3 study following FDA concurrence in July 2025.
Read more →ENTXEntera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Entera Bio Ltd. will present new clinical data from its Phase 2 trial of EB613 at the NAMS 2025 Annual Meeting. The data focuses on early postmenopausal women with low bone mass or osteoporosis, highlighting the potential of EB613 as an oral anabolic therapy. This marks Entera's first presentation at NAMS, emphasizing the need for accessible treatment options in this demographic.
Read more →ENTXEntera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Entera Bio has reported positive pharmacokinetic data for its first-in-class oral GLP-2 tablet aimed at treating Short Bowel Syndrome (SBS) during the 2025 ESPEN Congress. This oral therapy could significantly improve the treatment landscape for approximately 30,000 SBS patients who currently depend on daily injections. The collaboration with OPKO Health is expected to bolster the development of this innovative therapy.
Read more →ENTXEntera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
Entera Bio presented positive data on EB613 at the ASBMR 2025 Annual Meeting, highlighting significant improvements in both trabecular and cortical bone after six months of treatment in postmenopausal women with osteoporosis. The company plans to initiate a global Phase 3 study following FDA concurrence in July 2025. Additionally, promising pharmacokinetic data for a next-generation EB613 tablet candidate was shared.
Read more →ENTXEntera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Entera Bio Ltd. announced it will present data on three oral peptide programs at upcoming September conferences. The highlights include EB613, an oral anabolic treatment for postmenopausal osteoporosis, which has shown positive Phase 2 results. The company is preparing for a Phase 3 registration study with FDA alignment, indicating a significant step forward in their clinical development.
Read more →ENTXEntera Bio Announces Second Quarter 2025 Financial Results and Business Updates
Entera Bio Ltd. reported its Q2 2025 financial results, highlighting a pivotal FDA agreement for EB613's Phase 3 program. The company has a strong cash position of $18.9 million, enabling continued development of its pipeline, including oral therapies for osteoporosis and obesity. However, it also reported a net loss of $2.7 million, reflecting increased R&D expenses.
Read more →ENTX▲ +10.8%on this news
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Entera Bio has received FDA agreement to use bone mineral density (BMD) as the primary endpoint in its Phase 3 study for EB613, aimed at treating postmenopausal osteoporosis. This decision allows Entera to proceed without waiting for the qualification of BMD as a regulatory endpoint. The study will evaluate changes in total hip BMD over 24 months, with the incidence of vertebral fractures as a secondary endpoint. EB613 is positioned as the first oral anabolic treatment for osteoporosis.
Read more →ENTXOPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health and Entera Bio announced their abstract on a first-in-class oral GLP-2 analog for treating short bowel syndrome has been selected for presentation at the 2025 ESPEN Congress. This oral tablet aims to improve patient compliance compared to existing injectable therapies. The companies believe this innovation could enhance personalized care for patients suffering from this condition.
Read more →ENTXEntera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Entera Bio Ltd. announced that its new data on the oral anabolic treatment EB613 will be presented at the ASBMR 2025 Annual Meeting. The study demonstrates that EB613 effectively increases bone mineral density in postmenopausal women with osteoporosis. This oral tablet represents a potential shift in treatment for patients requiring anabolic intervention, addressing a gap left by current injectable therapies. The company's CEO emphasized the importance of this development in improving patient outcomes in osteoporosis management.
Read more →ENTXOPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
OPKO Health and Entera Bio announced that their investigational oral tablet OPK-88006 will be presented at the ENDO 2025 annual meeting. This dual GLP-1/glucagon agonist aims to provide treatment for obesity and metabolic disorders. The companies plan to file an Investigational New Drug application with the FDA later this year, with Phase 1 clinical studies in the pipeline.
Read more →ENTXEntera Bio Announces First Quarter 2025 Financial Results and Business Updates
Entera Bio Ltd. reported its financial results and business updates for Q1 2025, highlighting significant advancements in its oral peptide and protein replacement therapies. Key progress includes the promising performance of EB613, an oral anabolic treatment for osteoporosis, selected for presentation at the World Congress on Osteoporosis. The company has also extended its financial runway into late 2026 thanks to investments from key partners. Additionally, Entera is bolstering its leadership team to enhance strategic execution in women-centric health solutions.
Read more →ENTXEntera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
Entera Bio Ltd. presented positive results from its Phase 2 study of EB613 at the WCO-IOF-ESCEO Congress, showcasing its potential as a first-ever oral anabolic for postmenopausal women with osteoporosis. After six months of treatment, participants exhibited significant increases in bone mineral density compared to placebo, indicating early positive effects on both trabecular and cortical bone. The company aims to continue investigating the safety and efficacy of EB613 with plans for a Phase 3 trial. The results address a critical treatment gap for women at high risk of osteoporotic fractures.
Read more →ENTXEntera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. reported its financial results for the year ending December 31, 2024, highlighting key advancements in its oral peptide therapies for osteoporosis and obesity. Significant progress was noted with the EB613, an oral PTH(1-34) therapy for osteoporosis, and ongoing collaborations with OPKO Health. The company also reported improved financial health, with cash reserves sufficient to support operations through the third quarter of 2026. Regulatory developments related to the SABRE initiative may influence the pace of new treatment approvals for osteoporosis, a key focus area for Entera.
Read more →ENTXEntera Bio to Participate in Upcoming Events
Entera Bio Ltd. announced its participation in several upcoming healthcare conferences, including the Leerink Partners Global Healthcare Conference and the 2025 World Congress on Osteoporosis. At the World Congress, Entera will give an oral presentation and showcase a poster presentation, aiming to highlight its advancements in oral peptide and protein therapies. The company's involvement in these events demonstrates its commitment to innovation and engagement within the biopharma community.
Read more →ENTXEntera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference scheduled for February 11-12, 2025. The company will present an update led by CEO Miranda Toledano on February 11th. This virtual event presents a platform for Entera to engage with potential investors and discuss its business prospects.
Read more →ENTXEntera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. reported its Q3 2024 financial results, highlighting progress on pivotal clinical assets such as EB613 for osteoporosis. The company is poised for significant developments with its proprietary N-Tab platform, including ongoing trials for oral GLP-1/glucagon and GLP-2 peptide treatments. Entera also noted challenges, as it reported a net loss of $3.0 million for the quarter and projected cash reserves sufficient through Q3 2025, raising concerns about its financial sustainability. Leadership expressed optimism about pending FDA rulings that could impact their innovations in osteoporosis treatment.
Read more →ENTXEntera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Entera Bio and OPKO Health announced positive topline PK/PD results for their oral oxyntomodulin (OXM) tablet, aimed at treating obesity and metabolic disorders. The studies conducted in rodent and pig models demonstrated significant systemic exposure and a favorable PK profile for the oral formulation. Additionally, the treatment showed a statistically significant reduction in plasma glucose levels during a glucose tolerance test. The collaboration is on track to further develop this potential once-daily treatment with plans for data presentation at an upcoming clinical conference.
Read more →ENTXEntera Bio to Participate in Upcoming Investor and Scientific Conferences
Entera Bio Ltd. (NASDAQ: ENTX) has announced its participation in various upcoming investor and scientific conferences, including the H.C. Wainwright 26th Annual Global Investment Conference, the American Society for Bone and Mineral Research 2024 Annual Meeting, and the 7th Annual Evercore ISI HealthCONx Conference. These events offer Entera a platform to present its advancements in orally delivered peptides and small therapeutic proteins to potential investors and peers. The virtual and in-person conferences will take place between September and December 2024 in different locations.
Read more →ENTXEntera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. reported its Q2 2024 financial results, highlighting advancements in its N-Tab™ oral peptide programs. Anticipation is building for an FDA decision expected in five months concerning the ASBMR-FNIH SABRE regulatory endpoint, which is crucial for the company’s EB613 osteoporosis drug. Despite a slight year-over-year increase in net losses, the company maintains confidence in its financial projections and cash reserves, which are expected to cover operations into the third quarter of 2025. Positive clinical data has been published recently, suggesting a strong outlook for its investigational therapies.
Read more →ENTXEntera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
Entera Bio Ltd. announced that its research on EB613, a potential new oral treatment for post-menopausal women with high-risk osteoporosis, has been selected for presentation at the ASBMR 2024 Annual Meeting. EB613 is developed to be a once-daily mini tablet, addressing a significant need in osteoporosis management. The company also looks forward to sharing key updates on the SABRE study at the conference. Entera's efforts aim to provide accessible and effective treatment options for the estimated 200 million women globally who suffer from this condition.
Read more →ENTXEntera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024
Entera Bio Ltd. announced positive Phase 1 clinical data for its oral PTH(1-34) peptide candidate, EB612, aimed at treating hypoparathyroidism. The results were presented at the ENDO 2024 Annual Meeting, highlighting significant systemic exposure and favorable pharmacodynamic effects, including improvements in serum levels of calcium and vitamin D. No serious adverse events were reported, establishing EB612 as a promising oral alternative to injectable PTH therapies. The findings support Entera's innovative approach to peptide therapeutics via its N-Tab technology platform.
Read more →ENTXEntera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
Entera Bio Ltd. has announced the appointment of Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member. Dr. Wagman, who has extensive experience in metabolic bone disease and women's health, is recognized for her successful work in advancing osteoporosis treatments. Her addition is expected to enhance Entera's development capabilities in oral peptide therapeutics. The CEO emphasizes the advantage of her patient-focused approach as Entera continues to build its pipeline.
Read more →ENTXEntera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
Entera Bio Ltd. announced that it will present Phase 1 data for its oral PTH(1-34) tablet, EB612, at the ENDO 2024 Annual Meeting in Boston. The study focuses on developing a peptide replacement therapy for hypoparathyroidism, which traditionally requires multiple daily doses of calcium supplements. EB612 aims to enhance patient compliance by reducing administration frequency, with promising prior results from a Phase 2a study. The presentation is part of a significant advancement in treatment options for this condition.
Read more →ENTXEntera Bio Reports Q1 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. (NASDAQ: ENTX) reported Q1 2024 financial results and outlined significant business updates. The company is expanding its therapeutic pipeline, including pioneering oral treatments for osteoporosis and other conditions. Entera's cash reserves are sufficient to support operations through the third quarter of 2025, despite a net loss of $2.0 million this quarter. Additionally, the FDA is expected to provide a critical ruling that could facilitate further drug development efforts.
Read more →ENTXEntera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Entera Bio announced the publication of data from its Phase 2 trial of EB613, an oral PTH(1-34) peptide tablet for treating post-menopausal women with low bone mineral density or osteoporosis. The study, published in the Journal of Bone and Mineral Research, demonstrated significant increases in bone mineral density in patients, indicating the potential effectiveness of the treatment. It is positioned as the first oral, osteoanabolic medication designed to build bone, which could enhance patient adherence compared to injectable alternatives. No significant safety concerns were reported during the trial.
Read more →ENTXEntera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
Entera Bio Ltd. announced an important regulatory milestone for its product EB613, an oral treatment for osteoporosis. The FDA is expected to rule within 10 months on whether bone mineral density (BMD) can be used as a surrogate endpoint in trials for anti-osteoporosis drugs. This approval may allow EB613 to become the first oral anabolic medication in its class, addressing a significant unmet need in osteoporosis treatment. Positive results from previous studies and ongoing discussions with stakeholders suggest a strong potential for EB613 to improve patient outcomes in this area.
Read more →ENTX▲ +7.8%on this news· ran to +22% by day 1
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Entera Bio Ltd. has announced positive pharmacokinetic results from its research on a first-in-class oral GLP-2 peptide tablet intended for patients with short bowel syndrome. The oral formulation showed significant systemic exposure, with plasma levels approximately ten times higher than those achieved with the current injectable treatment, Gattex. This advancement may provide a more convenient option for patients facing compliance challenges with injectable therapies. The company is planning to further evaluate the therapeutic effects in vivo based on these promising results.
Read more →ENTXEntera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
Entera Bio Ltd. reported its financial results for 2023, marking a significant year focused on advancing its innovative N-Tab™ oral peptide technology. The company plans to initiate five new oral peptide programs by the end of 2025, subject to FDA approvals and other developments. Key product candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, among others. Despite reporting an $8.9 million net loss, Entera has managed to improve its operating expenses and ensures cash reserves are adequate to support operations through mid-2025.
Read more →ENTX▲ +19.4%on this news
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Entera Bio Ltd. has successfully regained compliance with NASDAQ's minimum bid price requirement, as confirmed by the notice received on March 1, 2024. The company maintained a closing bid price of at least $1.00 for 10 consecutive business days, thus addressing prior concerns over their listing. Entera continues to advance its innovative pipeline of oral peptide therapies, aiming to meet critical medical needs and enhance treatment standards in various conditions. The company is preparing to initiate Phase 3 studies for its leading product candidate, EB613, while further developing additional oral therapies.
Read more →ENTXEntera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, scheduled for February 13-14, 2024. CEO Miranda Toledano will present a business overview, emphasizing the company's focus on developing oral peptide therapies for unmet medical needs. Notably, Entera's candidate EB613 has shown promising results in clinical trials, moving towards a Phase 3 study expected in 2024. The company also deals with the inherent risks of clinical development and regulatory processes.
Read more →ENTXEntera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
Entera Bio Ltd. has received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement of $1.00 for continued listing. This extension allows the company until June 24, 2024, to achieve the necessary price for its shares, providing assurance that its current operations and trading status remain unaffected. However, failure to comply by the deadline may lead to a delisting process, which could involve appeals and other administrative steps.
Read more →ENTXEntera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
Entera Bio Ltd. has successfully closed a private placement, raising approximately $6.6 million and extending its cash runway into 2025. The company issued 7,916,879 units, consisting of ordinary shares and five-year warrants. Entera plans to utilize the net proceeds for general working capital purposes, while advancing its pipeline of orally delivered peptide therapies. Significant programs include EB613, which is set for a Phase 3 study targeting osteoporosis, and more innovative treatments for various conditions.
Read more →ENTXEntera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
Entera Bio Ltd. reported its Q3 2023 financial results, highlighting significant advancements in its development of oral peptide therapies. The company's CEO stated a goal to advance five potential programs into the clinic by the end of 2025, leveraging proprietary technology to improve peptide bioavailability. The pipeline includes promising candidates such as EB613 for osteoporosis and EB612 for hypoparathyroidism, as well as new collaborations aimed at treating short bowel syndrome and obesity. The company maintained a strong cash position to support these initiatives even amidst broader regional challenges.
Read more →ENTX▲ +20.6%on this newsshared move
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
Entera Bio Ltd. has announced a significant milestone in its EB613 Phase 3 program, as the ASBMR submitted a qualification plan to the FDA to use bone mineral density (BMD) as a surrogate endpoint for anti-osteoporosis drugs. This is the first such qualification plan submitted under the 21st Century Cures Act, which aims to streamline drug development processes. Entera's EB613, an oral treatment for osteoporosis, has demonstrated promising results in earlier phases, making it a potential leader in innovative treatments for the condition. The company prepares to initiate a Phase 3 study, capitalizing on the new regulatory pathway.
Read more →ENTXEntera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
Entera Bio presented promising data for its oral PTH(1-34) mini tablets at the ASBMR 2023 Annual Meeting. The results demonstrated rapid pharmacodynamic responses and consistent pharmacokinetics across different demographic groups. The lead formulation, EB613, showed significant improvements in bone mineral density in postmenopausal women with low BMD during a Phase 2 study. Entera Bio plans to initiate a Phase 3 registrational study for EB613, reflecting confidence in the therapeutic's potential.
Read more →ENTXEntera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Entera Bio Ltd. has announced a collaboration with OPKO Biologics to develop oral tablet formulations using Entera's oral delivery technology for peptides like GLP-2 and Oxyntomodulin. This partnership aims to address significant unmet medical needs related to obesity and intestinal malabsorption conditions. Entera's recent successes in pre-clinical trials augment the potential for a shift toward more convenient oral treatments compared to traditional injections. Specific details on the agreement's terms have not been disclosed.
Read more →ENTXEntera Bio to Participate in Upcoming Investor Conferences
Entera Bio Ltd. will participate in the H.C. Wainwright 25th Annual Global Investment Conference and the BIO Investor Forum, presenting key strategies and updates on their product candidates. The company is focusing on innovative peptide therapies, including EB613, which has shown promising results for osteoporosis. Entera plans to initiate a Phase 3 study for EB613, amidst various risk factors like regulatory hurdles and clinical uncertainties.
Read more →ENTX▲ +5%on this news
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
Entera Bio Ltd. has announced its participation in the ASBMR 2023 Annual Meeting, where it will present data on its investigational oral hPTH(1-34) peptide tablet therapy, EB613. This innovative treatment targets post-menopausal women at high risk of osteoporosis-related fractures. With an estimated 54 million adults at risk, EB613 is positioning itself as a much-needed solution, particularly for those who do not respond to existing treatments or cannot use injectable alternatives. The abstract presentations are scheduled for October 14 and 15, 2023, in Vancouver, BC, Canada.
Read more →ENTXEntera Bio Announces Q2 2023 Financial Results and Corporate Updates
Entera Bio Ltd. reported its Q2 2023 financial results, highlighting progress in its EB613 program aimed at treating high-risk osteoporosis. The company is advancing toward a Phase 3 study and expects data from its Phase 1B study in the latter half of 2023. Additionally, Entera has expanded its patent portfolio and reported a net loss of $4.5 million in the first half of the year, a decrease from the previous period. The management encouraged advancements in oral peptide formulations to meet unmet medical needs.
Read more →ENTXEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
Entera Bio Ltd. has appointed Haya Taitel, a seasoned leader from Sanofi, to its Board of Directors. Taitel's extensive experience in commercial strategy is expected to benefit Entera as it advances its phase 3 program for EB613, aimed at treating post-menopausal osteoporosis. The company is optimistic about the potential of EB613 to become a transformative therapy for the over 100 million women at risk of fractures globally. With Taitel's guidance, Entera plans to enhance its product pipeline and global strategy.
Read more →ENTX▼ -6.7%on this news
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
Entera Bio Ltd. announced its financial results and corporate updates for Q1 2023. The company highlighted the progress in discussions with the FDA for its Phase 3 study of EB613 targeting osteoporosis. Additionally, Entera is set to initiate a new PK study for treatment of hypoparathyroidism. Despite a positive outlook for its product candidates, the discontinuation of a collaboration with Amgen raises some concerns regarding future projects. Entera's financial health appears stable with reduced operating losses compared to the previous year.
Read more →ENTX▲ +10%on this newsshared move
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
Entera Bio Ltd. announced that its pre-clinical manuscript on oral delivery technology for GLP-2 analog teduglutide has been accepted for publication in the International Journal of Peptide Research and Therapeutics. This research aims to enable a first-in-class oral treatment for Short Bowel Syndrome (SBS) that currently requires daily injections. The manuscript, detailing Entera's innovative approach, highlights the company's commitment to transforming patient care in conditions requiring parenteral nutrition. Entera is also advancing other candidates designed to treat osteoporosis and hypoparathyroidism.
Read more →ENTX▼ -13.4%on this news· ran to -26% by day 3
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
Entera Bio Ltd. provided an update following its Type D Meeting with the FDA regarding its EB613 program for treating osteoporosis. The FDA expressed no opposition to the company's revised Phase 3 study protocol, including its use of Total Hip Bone Mineral Density as the primary endpoint. Additionally, the FDA found Entera's proposed population pharmacokinetic sampling approach reasonable. The company is optimistic about initiating the pivotal Phase 3 study pending final FDA guidance and aims to address significant medical needs in osteoporosis treatment.
Read more →ENTXEntera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
Entera Bio Ltd. announced its corporate milestones and financial results for 2022. The company is focusing on advancing its EB613 program for osteoporosis towards phase 3 readiness, addressing FDA feedback to optimize its study design. Financially, Entera reported a net loss of $13.1 million for the year and has cash reserves to support operations through mid-2024. However, uncertainties regarding regulatory approvals and study designs pose challenges as they seek funding for pivotal trials.
Read more →ENTXEntera Bio Regains Compliance with Nasdaq Listing Requirements
Entera Bio Ltd. announced it has regained compliance with NASDAQ's minimum bid price requirement, closing a previous warning regarding its share price. This compliance was confirmed as its ordinary shares traded above the $1.00 requirement for 14 consecutive business days. Entera continues to develop innovative therapies, including the clinical candidates EB613 and EB612, addressing unmet medical needs in osteoporosis and hypoparathyroidism. The company assures that it meets all necessary NASDAQ listing standards moving forward.
Read more →ENTX▲ +11%on this news
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Entera Bio Ltd. announced the acceptance of its Type D meeting protocol review by the U.S. FDA, a crucial step towards initiating a pivotal Phase 3 study for EB613, a novel oral treatment for post-menopausal osteoporosis. The results of a prior Phase 2 study indicated that EB613 met its primary and secondary endpoints. The FDA's agreement on the study's protocol marks significant progress, potentially supporting a New Drug Application (NDA) submission. Entera is preparing for the study's initiation anticipated in the second half of 2023, aligning with regulatory expectations.
Read more →ENTXEntera Bio to Participate in the SVB Securities Global Biopharma Conference
Entera Bio Ltd. (NASDAQ: ENTX) is set to present at the SVB Securities Global Biopharma Conference from February 13-16, 2023. The company is recognized for its development of orally delivered peptides and proteins, particularly the mini-tablet EB613 for osteoporosis. The presentation will highlight the company's advancements and ongoing collaboration with Amgen. Entera is actively pursuing regulatory approvals for its product candidates while navigating various clinical trial uncertainties.
Read more →ENTXEntera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the followi
Read more →ENTXEntera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced today the successful conclusion of its Type C meeting and agreement from the U.S.
Read more →ENTX▲ +6.6%on this news
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on the company’s lead
Read more →ENTXEntera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wa
Read more →ENTXEntera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced the details of “A Six-month Phase 2 Study of Oral PTH (EBP05) in Postmenopa
Read more →ENTXEntera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022. “W
Read more →ENTX▲ +6.8%on this news
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced the formation of its Clinical and Scientific Advisory Board (CSAB), consisti
Read more →ENTXEntera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted
Read more →ENTXEntera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company’s President of Research & Development and Founder, wil
Read more →ENTX▲ +9.8%on this news
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members, as Chief Business Offic
Read more →ENTXEntera Bio Reports First Quarter 2022 Financial Results and Business Highlights
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underway Company reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT BOSTON and JERUSALEM, May 12,
Read more →ENTX▲ +5%on this news
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May 05, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the devel
Read more →ENTXEntera Bio to Report First Quarter 2022 Financial Results on May 12
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursda
Read more →ENTXEntera Bio to Present at 2022 Maxim Virtual Growth Conference
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company will participate at the Maxim Virtual Growth Conference. Maxim Virtual Growth Co
Read more →ENTXEntera Bio Reports Financial Results for the Year Ended December 31, 2021
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 — — New EB612 formulation for Hypoparathyroidism trial planned in 2022 — — Oral delivery technology platform advances with more indications, inventions, patents, and collaborations — — Company to host conf
Read more →ENTXEntera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday
Read more →ENTXEntera Bio to Present at Aegis Virtual Conference on February 23rd
BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company’s Chief Executive Officer, Spiros Jamas, Sc.D., will present a company ove
Read more →ENTXEntera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH,
Read more →ENTX▼ -6%on this news
Entera Bio Reports Third Quarter 2021 Financial Results
‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 registrational trial in 2022 ‒ BOSTON and JERUSALEM, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the
Read more →ENTX▲ +5.4%on this news
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for osteoporosis and several other molecules now in development by Entera and in collabora
Read more →ENTXEntera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613 Linear Dose Responses Seen in Biomarker and Bone Mineral Density Data Pivotal Phase 3 registration study expected to commence 2022 BOSTON and JERUSALEM, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Entera B
Read more →ENTX▲ +5.7%on this news
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
‒ Second of Two Presentations to be Delivered by Entera ‒ ‒ Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ‒ BOSTON and JERUSALEM, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered lar
Read more →ENTXEntera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021. Entera is a leader in the
Read more →ENTXEntera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Co
Read more →ENTX▼ -7%on this news· ran to -18% by day 3
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for Planned Pivotal One-year Phase 3 Study Comparing Changes in Lumbar Spine BMD in Patients T
Read more →ENTXEntera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021, on August 16, 2021, at
Read more →ENTXEntera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month Biochemical Markers of Bone Formation and Resorption to be Presented ‒ ‒ Positioned to be
Read more →ENTXEntera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinic
Read more →ENTXEntera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months Subjects receiving the 2.5 mg dose of EB613 for 6 months had a significant placebo adjusted increase of 3.78% in lumbar spine
Read more →ENTXEntera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
‒ Oral delivery technology has potential to transform $20 billion injectable biologics market ‒ ‒ Final BMD results from company’s Phase 2 Osteoporosis study of EB 613 expected in Q2/2021 ‒ BOSTON and JERUSALEM, June 17, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX),
Read more →ENTXEntera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including GLP-2 and Human Growth Hormone ‒ ‒ Company to Host Conference Call and Webcast
Read more →ENTXEntera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld,
Read more →ENTXEntera Appoints Ramesh Ratan as Chief Financial Officer
BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Fi
Read more →ENTXEntera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables Initial U.S. Clinical Trial ‒ ‒ Amgen Collaboration Continues to Progress; Comp
Read more →ENTXEntera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, be
Read more →ENTXEntera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDA
Read more →ENTXEntera Bio To Present At The H.C. Wainwright Global Life Sciences Conference
BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Confere
Read more →ENTXEntera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research
‒ EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in Supplemental Calcium Usage – ‒ Oral Human Parathyroid Hormone (1-34) Has the Potential to Have a Major Impact on Compliance, Adherence, Therapeutic Impact and Quality of Life for Patients – BO
Read more →ENTXEntera Bio Initiates New Research Program For Oral GLP-2
‒ Program Leverages Entera’s Platform for Potential Development of Oral GLP-2 Analogs for Gastrointestinal and Other Indications ‒ ‒ GLP-2 Analogs Currently Administered Via Daily Injection to Treat Short Bowel Syndrome ‒ BOSTON, Mass. & JERUSALEM, Feb. 08, 2021 (GLOBE NEWSWIRE
Read more →ENTXEntera Bio Issues Letter to Shareholders
BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a me
Read more →ENTXEntera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
BOSTON and JERUSALEM, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has reviewed the company’s Investigational
Read more →ENTXEntera Bio Appoints Spiros Jamas as Chief Executive Officer
BOSTON and JERUSALEM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Spiros Jamas, Sc.D. to the role of Chief Executive Office
Read more →ENTXEntera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
‒ Completed Enrollment in Phase 2 Clinical Trial of EB613, Positioned as the First Potential Oral Bone Building Product to Treat Osteoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density (BMD) Data Reported in Phase 2 EB613 Clinical Trial ‒ ‒ Company Expects to Report Biom
Read more →ENTXEntera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020,
Read more →ENTXEntera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis
‒ Company Expects to Report Interim 3 Month Biomarker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒ ‒ Results Expected Are Expected to Inform the Design of Potential Global Phase 3 Clinical Trial ‒ BOSTON and JERUSALEM
Read more →ENTXEntera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference
BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C. Wainwright Annual Israel
Read more →ENTXEntera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment
Read more →ENTXEntera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner – ‒ Company Expects to Complete Patient Enrollment in Q3:20 and Report Interim Biomarker Data from 2.5 mg Dose in Q1:21 with Final Data
Read more →ENTXEntera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020
BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, bef
Read more →ENTXENTERA BIO ANNOUNCES MANAGEMENT CHANGES BOSTON, Massachusetts & JERUSALEM, Israel (
ENTERA BIO ANNOUNCES MANAGEMENT CHANGES BOSTON, Massachusetts & JERUSALEM, Israel (August 10, 2020) - Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Roger Ga
Read more →ENTXEntera Bio Announces Management Changes
BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Roger Garceau as Interim Chief Executive Officer, effecti
Read more →ENTXEntera Bio to Present at BTIG’s Virtual Biotechnology Conference
BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Mo
Read more →ENTXEntera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results
‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒ ‒ Oral PTH Described by Clinicians as Potential Game-Changer that Addresses Substantial Unmet Need with Possibility of Improving Patient Compl
Read more →ENTXEntera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis
‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒ ‒ Company Continues to Expect Completion of Enrollment in Q3:20 and Intends to Follow All Patients for Bone Mineral Density and B
Read more →ENTXEntera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒ ‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six Months for Bone Mineral Density Data and Evaluate Additional Higher Doses o
Read more →ENTXEntera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020
BOSTON and JERUSALEM, May 07, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report interim three-month top-line biomarker data for the first 50% of the patients enrolled in t
Read more →ENTXENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019
‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒ ‒ Financing Completed in December 2019 Funds Company into the Second Quarter of 2021 ‒ ‒ Company to Host Conf
Read more →ENTXENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020
BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report financial and business results for the quarter and year ended December 31, 2019, on March
Read more →ENTXEntera Bio Announces the Completion of $14.3 million Private Placement
BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering (the
Read more →ENTXEntera Announces Closing of Private Placement
BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a private placement offering (the “Offering”) with a select group of accredited invest
Read more →ENTXEntera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update
Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020 Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients. Conference call and live webcast today at 8:30 am Eastern Time BOSTON a
Read more →ENTXEntera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer
BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, fi
Read more →ENTXEntera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019
BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S. financial markets open on Thursday, November 21, 2019. The
Read more →ENTXEntera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting Data suggest favorable pharmacologic and pharmacokinetic profiles of Entera’s Oral PTH formulation with a f
Read more →ENTXEntera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at
Read more →ENTXEntera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update
Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented in Q3 2019. Appointed Adam Gridley as Chief Executive Officer Conference call
Read more →ENTXEntera Bio to Announce Second Quarter and Six Months ended June 30, 2019 Financial Results on Tuesday, August 20, 2019
JERUSALEM, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before the U.S. financial markets open on Tuesday, August 20, 2019. The Company will host
Read more →ENTXEntera Bio Appoints Adam Gridley as Chief Executive Officer
JERUSALEM, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip Schwartz, Ph.D., former CEO of Entera since the Company’s inception in 2010, will contin
Read more →ENTXEntera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH
JERUSALEM, July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluat
Read more →ENTXEntera Bio Reports First Quarter 2019 Financial Results and Operating Update
Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical analysis are ongoing, with results expected to be presented in 2H 2019. Appointed Dana Yaacov-Garbeli,
Read more →ENTXEntera Bio Announces 20-F Filing
JERUSALEM, March 28, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission. A copy of the Annual Report available in the Inves
Read more →ENTXEntera Bio Reports 2018 Annual Financial Results and Operating Update
Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosis Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, Amgen’s exercise of options to select additional
Read more →ENTXEntera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28
JERUSALEM, March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018 before the market open on Thursday, March 28, 2019. The Company will host a conference call
Read more →ENTXEntera Bio Announces a Transition in the Chief Financial Officer Position
JERUSALEM, March 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that Mira Rosenzweig, Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms. Rosenzwe
Read more →ENTXEntera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis
JERUSALEM, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis. The
Read more →ENTXEntera Bio Reports Third Quarter 2018 Financial Results and Operating Update
Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, as well as royalties on commercial sales Met with FDA in late November 2018 to discuss clinical development plan for EB613 in the treatment of osteoporos
Read more →ENTXEntera Bio Appoints Gerald M. Ostrov to Board of Directors
JERUSALEM, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors, effective immediately. “We are pleased to have Jerry join our Board of Directors. He brings wi
Read more →ENTXEntera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses
Amgen will have the option to advance up to three large molecule programs using Entera’s oral delivery technology Entera will be eligible to receive up to $270 million in clinical and commercial milestone payments JERUSALEM, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Na
Read more →ENTXEntera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
Demonstrates positive results in three metabolic parameters in patients with hypoparathyroidism treated with Oral PTH (1-34) Reports a significant decrease in 24-hour urinary calcium in hypoparathyroid patients treated with Oral PTH (1-34) JERUSALEM, Israel, Nov. 08, 2018 (GLOB
Read more →ENTXEntera Bio Appoints Two New External Independent Members to the Board of Directors
JERUSALEM, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately. The appointments of Ms. Charles and Ms. Toledano were appr
Read more →ENTXEntera Bio Appoints Dr. Arthur Santora as Chief Medical Officer
JERUSALEM, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II, MD, PhD as its new Chief Medical Officer, effective immediately. Dr. Santora has more than 30 years of experience in the biotech indust
Read more →ENTXEntera Bio Reports Second Quarter 2018 Financial Results and Operating Update
Closed Initial Public Offering on July 2, 2018 Completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients Mr. Gerald Lieberman was Appointed as Chairman of the Board of Directors JERUSALEM, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW
Read more →ENTXEntera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors
JERUSALEM, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as of August 6, 2018. “I am honored to be appointed Chairman of Entera Bio and look
Read more →ENTXEntera Bio Completes Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients
A second and final part of the study will evaluate selected dose regimens chosen based on part 1 JERUSALEM, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has completed the first part of the PK/PD study in hypoparathyroidism patients wi
Read more →ENTXEntera Bio Ltd. Announces Closing of Initial Public Offering
JERUSALEM, July 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (NASDAQ:ENTXW), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics, announced today the closing of its initial publi
Read more →ENTXEntera Bio Ltd. Announces Pricing of Initial Public Offering
JERUSALEM, June 28, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (NASDAQ:ENTXW), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics, announced today the pricing of its initial publi
Read more →Competitive Position
How ENTX ranks across every disease it competes inCompetitive Position is a premium feature
See how ENTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial